Are you Dr. Nottage?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 19 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
262 Danny Thomas Pl
Memphis, TN 38105Phone+1 901-595-6216Fax+1 901-595-2952
Summary
- Dr. Kerri Nottage, MD is a pediatric hematologist/oncologist in Memphis, Tennessee. She is currently licensed to practice medicine in Tennessee and New Jersey. She is affiliated with Le Bonheur Children's Hospital.
Education & Training
- Brown UniversityResidency, Internal Medicine/Pediatrics, 2004 - 2008
- The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
- NJ State Medical License 2016 - 2023
- TN State Medical License 2009 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Pediatrics
Clinical Trials
- Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease Start of enrollment: 2006 Mar 03
- Transfusional Iron Overload Among Leukemia Survivors Start of enrollment: 2013 Oct 18
Publications & Presentations
PubMed
- 2 citationsCusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose opti...Thomas Pabst, Cristina Papayannidis, Fatih Demirkan, Vadim Doronin, Laura M Fogliatto
The Lancet. Haematology. 2023-11-01 - 15 citationsResults from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemo...Thomas Pabst, Norbert Vey, Lionel Adès, Ulrike Bacher, Mario Bargetzi
Haematologica. 2023-07-01 - 5 citationsIbrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.G A Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz
Blood Advances. 2023-02-28